No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

BACKGROUND Prostate cancer mortality in the United States has declined by nearly 40% over the last 25 years. However, to the authors' knowledge, the contribution of prostate-specific antigen (PSA) screening for the early detection of prostate cancer remains unclear and controversial. In the current study, the authors attempted to determine whether improvements in survival over time among patients with metastatic prostate cancer have contributed to the decline in mortality. METHODS Men aged ≥ 45 years who presented with de novo metastatic prostate cancer from 1988 to 2009 were identified within the California Cancer Registry. Overall survival and disease-specific survival were estimated using the Kaplan-Meier method. A multivariate analysis with Cox proportional hazards modeling was performed to adjust for different distributions of variables between groups. RESULTS A total of 19,336 men presented with de novo metastatic prostate cancer during the study period. On multivariate analysis, overall survival was found to be better for men diagnosed from 1988 through 1992 and 1993 through 1998 than for men diagnosed in the most recent era (hazards ratio, 0.78; 95% confidence interval, 0.72-0.85 [P <.001] and HR, 0.79; 95% confidence interval, 0.74-0.86 [P <.001]). There was no improvement in disease-specific survival observed when comparing the most contemporary men (those diagnosed between 2004 and 2009) with those diagnosed between 1988 and 1997. CONCLUSIONS In this analysis of men presenting with de novo metastatic prostate cancer, no consistent improvement in overall or disease-specific survival could be demonstrated over time. These data suggest that improvements in survival for patients with advanced disease have not contributed substantially to the observed drop in prostate cancer mortality over the PSA era and that stage migration secondary to PSA screening plays a more prominent role. Cancer 2014;120:818-823.

Original languageEnglish (US)
Pages (from-to)818-823
Number of pages6
JournalCancer
Volume120
Issue number6
DOIs
StatePublished - Mar 15 2014

Fingerprint

Prostatic Neoplasms
Survival
Prostate-Specific Antigen
Mortality
Multivariate Analysis
Confidence Intervals
Early Detection of Cancer
Registries
Neoplasms

Keywords

  • metastasis
  • prostate cancer
  • prostate-specific antigen
  • survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. / Wu, Jennifer N.; Fish, Kari M.; Evans, Christopher P; deVere White, Ralph W; Dall'Era, Marc.

In: Cancer, Vol. 120, No. 6, 15.03.2014, p. 818-823.

Research output: Contribution to journalArticle

@article{9e63946a4d194385b2e3a18ad8690af9,
title = "No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period",
abstract = "BACKGROUND Prostate cancer mortality in the United States has declined by nearly 40{\%} over the last 25 years. However, to the authors' knowledge, the contribution of prostate-specific antigen (PSA) screening for the early detection of prostate cancer remains unclear and controversial. In the current study, the authors attempted to determine whether improvements in survival over time among patients with metastatic prostate cancer have contributed to the decline in mortality. METHODS Men aged ≥ 45 years who presented with de novo metastatic prostate cancer from 1988 to 2009 were identified within the California Cancer Registry. Overall survival and disease-specific survival were estimated using the Kaplan-Meier method. A multivariate analysis with Cox proportional hazards modeling was performed to adjust for different distributions of variables between groups. RESULTS A total of 19,336 men presented with de novo metastatic prostate cancer during the study period. On multivariate analysis, overall survival was found to be better for men diagnosed from 1988 through 1992 and 1993 through 1998 than for men diagnosed in the most recent era (hazards ratio, 0.78; 95{\%} confidence interval, 0.72-0.85 [P <.001] and HR, 0.79; 95{\%} confidence interval, 0.74-0.86 [P <.001]). There was no improvement in disease-specific survival observed when comparing the most contemporary men (those diagnosed between 2004 and 2009) with those diagnosed between 1988 and 1997. CONCLUSIONS In this analysis of men presenting with de novo metastatic prostate cancer, no consistent improvement in overall or disease-specific survival could be demonstrated over time. These data suggest that improvements in survival for patients with advanced disease have not contributed substantially to the observed drop in prostate cancer mortality over the PSA era and that stage migration secondary to PSA screening plays a more prominent role. Cancer 2014;120:818-823.",
keywords = "metastasis, prostate cancer, prostate-specific antigen, survival",
author = "Wu, {Jennifer N.} and Fish, {Kari M.} and Evans, {Christopher P} and {deVere White}, {Ralph W} and Marc Dall'Era",
year = "2014",
month = "3",
day = "15",
doi = "10.1002/cncr.28485",
language = "English (US)",
volume = "120",
pages = "818--823",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period

AU - Wu, Jennifer N.

AU - Fish, Kari M.

AU - Evans, Christopher P

AU - deVere White, Ralph W

AU - Dall'Era, Marc

PY - 2014/3/15

Y1 - 2014/3/15

N2 - BACKGROUND Prostate cancer mortality in the United States has declined by nearly 40% over the last 25 years. However, to the authors' knowledge, the contribution of prostate-specific antigen (PSA) screening for the early detection of prostate cancer remains unclear and controversial. In the current study, the authors attempted to determine whether improvements in survival over time among patients with metastatic prostate cancer have contributed to the decline in mortality. METHODS Men aged ≥ 45 years who presented with de novo metastatic prostate cancer from 1988 to 2009 were identified within the California Cancer Registry. Overall survival and disease-specific survival were estimated using the Kaplan-Meier method. A multivariate analysis with Cox proportional hazards modeling was performed to adjust for different distributions of variables between groups. RESULTS A total of 19,336 men presented with de novo metastatic prostate cancer during the study period. On multivariate analysis, overall survival was found to be better for men diagnosed from 1988 through 1992 and 1993 through 1998 than for men diagnosed in the most recent era (hazards ratio, 0.78; 95% confidence interval, 0.72-0.85 [P <.001] and HR, 0.79; 95% confidence interval, 0.74-0.86 [P <.001]). There was no improvement in disease-specific survival observed when comparing the most contemporary men (those diagnosed between 2004 and 2009) with those diagnosed between 1988 and 1997. CONCLUSIONS In this analysis of men presenting with de novo metastatic prostate cancer, no consistent improvement in overall or disease-specific survival could be demonstrated over time. These data suggest that improvements in survival for patients with advanced disease have not contributed substantially to the observed drop in prostate cancer mortality over the PSA era and that stage migration secondary to PSA screening plays a more prominent role. Cancer 2014;120:818-823.

AB - BACKGROUND Prostate cancer mortality in the United States has declined by nearly 40% over the last 25 years. However, to the authors' knowledge, the contribution of prostate-specific antigen (PSA) screening for the early detection of prostate cancer remains unclear and controversial. In the current study, the authors attempted to determine whether improvements in survival over time among patients with metastatic prostate cancer have contributed to the decline in mortality. METHODS Men aged ≥ 45 years who presented with de novo metastatic prostate cancer from 1988 to 2009 were identified within the California Cancer Registry. Overall survival and disease-specific survival were estimated using the Kaplan-Meier method. A multivariate analysis with Cox proportional hazards modeling was performed to adjust for different distributions of variables between groups. RESULTS A total of 19,336 men presented with de novo metastatic prostate cancer during the study period. On multivariate analysis, overall survival was found to be better for men diagnosed from 1988 through 1992 and 1993 through 1998 than for men diagnosed in the most recent era (hazards ratio, 0.78; 95% confidence interval, 0.72-0.85 [P <.001] and HR, 0.79; 95% confidence interval, 0.74-0.86 [P <.001]). There was no improvement in disease-specific survival observed when comparing the most contemporary men (those diagnosed between 2004 and 2009) with those diagnosed between 1988 and 1997. CONCLUSIONS In this analysis of men presenting with de novo metastatic prostate cancer, no consistent improvement in overall or disease-specific survival could be demonstrated over time. These data suggest that improvements in survival for patients with advanced disease have not contributed substantially to the observed drop in prostate cancer mortality over the PSA era and that stage migration secondary to PSA screening plays a more prominent role. Cancer 2014;120:818-823.

KW - metastasis

KW - prostate cancer

KW - prostate-specific antigen

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84896714985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896714985&partnerID=8YFLogxK

U2 - 10.1002/cncr.28485

DO - 10.1002/cncr.28485

M3 - Article

VL - 120

SP - 818

EP - 823

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -